Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis
- 2 January 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 20 (1) , 1-11
Abstract
Quadrivalent Influenza Vaccine (Sinovac Biotech) is a quadrivalent split-virion-inactivated influenza vaccine approved in China in June 2020 for individuals ≥3 years of age. It contains 15 µg hemag...Keywords
Funding Information
- the National Major Scientific and Technological Special Project of China
This publication has 47 references indexed in Scilit:
- Review of 10 years of clinical experience with Chinese domestic trivalent influenza vaccine Anflu®Human Vaccines & Immunotherapeutics, 2013
- The evolving history of influenza viruses and influenza vaccinesExpert Review of Vaccines, 2013
- Immunogenicity and safety of three 2010–2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adultsHuman Vaccines & Immunotherapeutics, 2013
- Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 yearsBMC Infectious Diseases, 2013
- Seasonal Influenza Vaccine Effectiveness among Children Aged 6 to 59 Months in Southern ChinaPLOS ONE, 2012
- H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on StudyClinical Infectious Diseases, 2012
- A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adultsVaccine, 2011
- Seasonal influenza: The burden of disease in childrenVaccine, 2011
- Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarityVaccine, 2010
- A VIRUS OBTAINED FROM INFLUENZA PATIENTSThe Lancet, 1933